BioCryst Pharmaceuticals
Nasdaq BCRX · Durham, NC
Works in Cardiovascular · Dermatology · Genetic & rare · Hematology · Immunology · Infectious disease · Renal & urogenital · Respiratory · Women's health
BioCryst Pharmaceuticals is a clinical trial sponsor based in Durham, NC, listed as Nasdaq BCRX. It has 3 active clinical trials with 246 planned participants, across 9 therapeutic areas. Since 2021 it has completed 11 trials and stopped 10 early.
Trial track record · since 2021
Financials · Nasdaq BCRX
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
3 approved drug applications with a product on the market.
Questions about BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 246 planned participants, in Cardiovascular, Dermatology, Genetic & rare, Hematology and other areas. Since 2021 it has completed 11 trials and stopped 10 early.
BioCryst Pharmaceuticals is based in Durham, NC and is listed as Nasdaq BCRX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BioCryst Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-27.
Approve Suite is not affiliated with BioCryst Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.